Literature DB >> 7795104

Risks of chronicity following acute hepatitis B virus infection: a review.

K C Hyams1.   

Abstract

A bibliographic search was conducted of English-language articles dealing with chronic hepatitis B virus (HBV) infection to evaluate the risk of chronicity following acute infection. Chronic HBV infection was defined as carriage of hepatitis B surface antigen (HBsAg) for at least 6 months. On the basis of incidence studies employing standard serological test methods, the highest risk (80%-90%) of chronic infection was found to be among infected neonates born to hepatitis B e antigen-positive carrier mothers. Of children infected before 6 years of age, chronic infection was reported to develop in approximately 30%. A relatively wide range of risks (< 1%-12%) was found among diverse populations of older children and adults. However, most of the 10 identified incidence studies of generally healthy adults indicated that the risk of chronicity is very low: < or = 5% in eight studies. In addition, the pooled incidence of chronicity was < 5% among two different adult population groups: initially uninfected subjects, who usually experienced asymptomatic infection, and patients presenting with acute hepatitis B. In addition to the primary influence of age, the studies revealed a higher risk of chronic HBV infection among males and among patients with impaired immunity due to various causes.

Entities:  

Mesh:

Year:  1995        PMID: 7795104     DOI: 10.1093/clinids/20.4.992

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  119 in total

1.  Accuracy of perceptions of hepatitis B and C status. Injecting drug users need vaccination against hepatitis B.

Authors:  M E Ramsay; M A Balogun; C G Teo; P P Mortimer
Journal:  BMJ       Date:  2000-02-19

2.  Controlling perinatally acquired hepatitis B.

Authors:  F Abass; R D Thomas; A Rajkumar; N Gupta; J M Puliyel
Journal:  Indian J Pediatr       Date:  2001-04       Impact factor: 1.967

3.  Hepatitis A, B, and C.

Authors:  R Gilson; M G Brook
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.

Authors:  Sara Boccalini; Cristina Taddei; Vega Ceccherini; Angela Bechini; Miriam Levi; Dario Bartolozzi; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

6.  The effects of booster vaccination on hepatitis B vaccine in anti-HBs negative infants of HBsAg-positive mothers after primary vaccination.

Authors:  Hua Gu; Jun Yao; Wei Zhu; Huakun Lv; Suyun Cheng; Luoya Ling; Shichang Xia; Yongdi Chen
Journal:  Hum Vaccin Immunother       Date:  2013-02-19       Impact factor: 3.452

7.  Epidemiology of hepatitis B virus infection in Albania.

Authors:  Bashkim Resuli; Skerdi Prifti; Bledar Kraja; Tatjana Nurka; Mimoza Basho; Edita Sadiku
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

8.  Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Authors:  Chloe L Thio; Jacquie Astemborski; Arman Bashirova; Timothy Mosbruger; Spencer Greer; Mallory D Witt; James J Goedert; Margaret Hilgartner; Audrey Majeske; Stephen J O'Brien; David L Thomas; Mary Carrington
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 9.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

10.  The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.

Authors:  Michael L Landrum; Ann M Fieberg; Helen M Chun; Nancy F Crum-Cianflone; Vincent C Marconi; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; Glenn Wortmann; Brian K Agan
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.